Molecular Templates MTEM is a clinical stage Biotechnology company focused on the discovery, development and commercialization of next generation immunotoxins called engineered toxin bodies (ETBs for the treatment of cancer. Backed by a very strong syndicate of investors, MTEM went public via Reverse Merger in August 2017. In June of [...]
Athenex Athenex Inc (ATNX) is a Global Biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. They are working to bring innovative cancer treatments (Oral Taxil) to the market and improve health outcomes. Senior members of the Laidlaw Capital markets team have [...]
Case Study: Aldeyra Therapeutics In May of 2014 Aldeyra Therapeutics (ALDX), a late stage clinical development biotechnology company developing and commercializing next generation medicines for patients with immune mediated, ocular and systemic diseases completed a $12,000,000, retail centric IPO. Since then, the company has raised over $125,000,000. Following the company’s IPO, [...]